Clinical trials: Cancer, Advanced
Lymphoma
Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells.
- Trial name
- NCT00002618
- Testing
- filgrastim, cytarabine, doxorubicin hydrochloride
- Where
- 10 sites in United States, Puerto Rico and 1 more
- Volunteers
- 242 people
- Sponsor
- Children's Oncology Group
Advanced Cancer
Randomized Controlled Trial of the Meaning-Making Intervention (MMi)
Research questions: Pilot study research questions: Primary: 1)Can we recruit a sufficient number (i.e., at least 60 patients over 9 months) and retain a sufficient proportion of both men and women (i.e., at least 80% at 2, 4, or…
- Trial name
- NCT01693991
- Testing
- Meaning-Making intervention (MMi), Empathic visitor
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Jewish General Hospital
Solid Tumor
Autologous Tumour Vaccine Trial
Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid…
- Trial name
- NCT05807035
- Testing
- Radvax
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Vaxine Pty Ltd
Tumor, Tumor, Solid
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer
- Trial name
- NCT05103358
- Testing
- nab-sirolimus
- Where
- 166 sites in United States, Puerto Rico and 1 more
- Volunteers
- 128 people
- Sponsor
- Aadi Bioscience, Inc.
Fatigue
PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care
The objective of this study is to conduct a trial in the spirit of providing as much as possible the benefit of PG2 treatment to eligible patients and to evaluate the efficacy and safety of PG2 for relieving fatigue among…
- Trial name
- NCT00523107
- Testing
- PG2
- Where
- Taiwan
- Volunteers
- 91 people
- Sponsor
- PhytoHealth Corporation
Pediatric Cancer, Solid Tumor Pediatric
Durvalumab and Tremelimumab for Pediatric Malignancies
The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the…
- Conditions
- Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
- Trial name
- NCT03837899
- Testing
- Durvalumab / Tremelimumab Combination Therapy
- Where
- 19 sites in United States, France and 5 more
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00096096
- Testing
- mycophenolate mofetil, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent).
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT04268550
- Testing
- Selpercatinib
- Where
- 306 sites in United States
- Volunteers
- 124 people
- Sponsor
- SWOG Cancer Research Network
Gastrointestinal Stromal Tumor, Sarcoma
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally…
- Trial name
- NCT00041249
- Testing
- brostallicin
- Where
- 16 sites in Belgium, France and 3 more
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Rectal Cancer, Neoplasm Metastasis
A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer
The purpose of this trial is to study the efficacy of preoperative radiation therapy and capecitabine in locally advanced rectal cancer.
- Trial name
- NCT00122291
- Testing
- Capecitabine, Pelvic radiation
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- Alberta Health services
Ovarian Cancer
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
RATIONALE: Chemosensitizers may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug.
- Trial name
- NCT00003214
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- 10 sites in Switzerland
- Volunteers
- 300 people
- Sponsor
- Swiss Cancer Institute
Cervical Cancer
Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have advanced…
- Trial name
- NCT00016926
- Testing
- capecitabine
- Where
- 10 sites in United States, Norway
- Sponsor
- Gynecologic Oncology Group
Pancreatic Neoplasms
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas
- Trial name
- SPTP (NCT06914674)
- Testing
- Tamoxifen 20 mg
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Advanced Lung Cancer
A Pilot Study of the VosCryoTM Breathalyser in Lung Cancer
CryoPilot is a single-centre pilot study being conducted at Weston Park Cancer Centre in Sheffield, UK. The goal of this pilot study is to determine whether small-volume exhaled breath condensate sample (EBC) obtained via a…
- Trial name
- CryoPilot (NCT07689968)
- Testing
- Expiratory Breath Condensate Collection
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Melanoma (Skin)
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070343
- Testing
- oblimersen sodium, dacarbazine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Ewing Sarcoma, Colorectal Adenocarcinoma
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
- Trial name
- NCT03715933
- Testing
- INBRX-109, Irinotecan, Temozolomide
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 411 people
- Sponsor
- Inhibrx Biosciences, Inc
Prostate Cancer
A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
This study is a large observational study, set-up to observe how long-term treatment with FIRMAGON (hormone regulator) compare to other treatments in regards to cardiovascular events, changes in bone density, changes in blood…
- Trial name
- NCT01234350
- Where
- 160 sites in Belgium, Denmark and 13 more
- Volunteers
- 1,493 people
- Sponsor
- Ferring Pharmaceuticals
Advanced Solid Tumor
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the…
- Trial name
- MYTHIC (NCT04855656)
- Testing
- Lunresertib, RP-3500, Zedoresertib
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 464 people
- Sponsor
- Debiopharm International SA
Non-small Cell Lung Cancer, Radiation Toxicity
Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy
Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curative-intent concurrent…
- Trial name
- RICT-LUNG (NCT03416972)
- Testing
- Standard platinum-based chemoradiotherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Carcinoma, Non-small-cell Lung
A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
This is a study of the safety and effectiveness of atezolizumab in participants with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy.
- Trial name
- NCT03321695
- Where
- Argentina
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.